UBB2048 / Unity Biotech - LARVOL DELTA

A novel Tie2xVEGF bispecific antibody fusion demonstrates enhanced therapeutic efficacy through direct Tie2 activation and VEGF neutralization. (PubMed, J Transl Med) - "These findings demonstrate that a therapeutic strategy combining direct Tie2 activation and VEGF blockade may provide improved therapeutic potential compared to neutralizing VEGF alone or Ang2 and VEGF, representing a promising therapeutic strategy that warrants further validation for the treatment of various ocular diseases."

Journal • Ophthalmology • Retinal Disorders • FLT1 • NOS3

A novel tri-functional antibody integrating Tie2 activation, VEGF inhibition, and Ang-2 blockade delivers superior retinal vascular outcomes beyond current therapies (ARVO 2026) - "Results MT-103 robustly activated Tie2, more effectively inhibited VEGF signaling, and reduced endothelial hyperpermeability compared with faricimab and other comparators...In multiple laboratory and animal studies, MT-103 improved vessel stability, reduced leakage and inflammation, and preserved key supporting cells more effectively than existing treatments. These findings suggest that MT-103 could offer a promising new therapeutic option for people with retinal vascular diseases."

Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders